Omeprazole (A2845): Technical Guidance for Gastric Acid Secretion Research

What This Product Solves

Omeprazole, chemically identified as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, is a high-purity H+,K+-ATPase inhibitor supplied by APExBIO for use in scientific research. Its primary function is to enable precise inhibition of gastric H+,K+-ATPase, a key enzyme driving gastric acid secretion. The product’s validated IC50 values (5.8 μM for H+,K+-ATPase; 0.16 μM for histamine-induced acid formation) and chemical stability make it a reliable choice for researchers studying gastric acid-related disorders and peptic ulcer disease models. Omeprazole is not intended for human or animal therapeutic applications, nor for diagnostic use.

For researchers requiring reproducible suppression of acid secretion in cellular or animal models, Omeprazole (A2845) offers a standardized, quality-controlled reagent. Its solubility profile and storage requirements are engineered for laboratory workflows, supporting antiulcer activity studies and mechanistic experiments on gastric acid regulation.

For broader context on proton pump inhibition in gastric research, the article "Omeprazole: H+,K+-ATPase Inhibitor for Gastric Acid Research" discusses assay design strategies. Additionally, the review "Applied Use Cases of 3-(quinolin-4-ylmethylamino)... in Gastric Models" details protocol implementation and troubleshooting for this compound.

Protocol Parameters

• Assay: H+,K+-ATPase inhibition | Value: IC50 = 5.8 μM | Applicability: Used for dose-response and potency benchmarking in enzyme activity assays | Rationale: Demonstrates compound’s inhibitory efficacy in vitro | Source: product information
• Assay: Histamine-induced acid formation inhibition | Value: IC50 = 0.16 μM | Applicability: Suitable for cell-based or ex vivo acid secretion models | Rationale: Allows assessment of antiulcer activity at physiologically relevant targets | Source: product information
• Assay: Solubility in DMSO | Value: ≥17.27 mg/mL | Applicability: Stock solution preparation for in vitro and in vivo dosing | Rationale: Ensures sufficient concentration for working aliquots and serial dilutions | Source: product information
• Assay: Long-term solution storage | Value: Not recommended | Applicability: Solution should be freshly prepared before use | Rationale: Maintains compound integrity and reproducibility | Source: product information
• Assay: Working concentration range | Value: 0.1–10 μM (workflow recommendation) | Applicability: Titration for cell or tissue assays | Rationale: Empirically determined to optimize target inhibition while minimizing off-target effects | Source: workflow recommendation

Workflow Setup and QC Checklist

• Compound Handling: Store Omeprazole as a solid at -20°C for maximum stability. Avoid repeated freeze-thaw cycles.
• Stock Solution Preparation: Dissolve Omeprazole in DMSO to create stock solutions at concentrations up to 17.27 mg/mL. Vortex until fully dissolved. Prepare working dilutions in assay buffer immediately before use.
• Aliquoting: Divide bulk stock into single-use aliquots to reduce degradation risk from freeze-thaw exposure.
• Quality Control: Confirm compound identity and purity (~98%) via certificate of analysis from supplier. Visually inspect for precipitation before each use.
• Documentation: Record batch numbers, storage conditions, and solution preparation details for each experiment to ensure reproducibility.
• Shipping Considerations: Plan for blue ice shipment if receiving small molecule orders to maintain cold chain integrity.

Common Failure Modes and Fixes

• Precipitation in Working Solutions: If precipitation occurs after dilution, verify DMSO content does not fall below compound solubility threshold. Adjust DMSO to at least 0.1–1% in final assay media if compatible with biological system.
• Reduced Inhibitory Potency: Degradation may result from improper storage or use of aged solutions. Always prepare fresh working dilutions and avoid long-term storage of dissolved Omeprazole.
• Batch-to-Batch Variability: Ensure that only validated, high-purity material is used and that all workflow steps are documented. Cross-verify IC50 activity regularly using internal standards or controls.
• Solubility Issues in Alternative Vehicles: Omeprazole is insoluble in water and ethanol; avoid attempting dissolution in these solvents.

Scope and Limitations

• Intended Use: This compound is intended strictly for laboratory research. Do not use for clinical, diagnostic, or in vivo therapeutic applications.
• Model Systems: Designed for gastric acid secretion research, antiulcer activity study, and investigation of proton pump inhibition in cellular and animal models. Not validated for use outside these domains.
• Compatibility: DMSO vehicle compatibility must be confirmed for each assay system to avoid solvent-related artifacts.
• Documentation: The absence of direct peer-reviewed publication data for this specific SKU requires that all findings be independently validated within each laboratory context.

Conclusion

Omeprazole (A2845) from APExBIO is a robust reagent for targeted inhibition of gastric H+,K+-ATPase in experimental workflows. Its validated potency, solubility profile in DMSO, and strict quality control measures make it suitable for antiulcer and gastric acid secretion research. Adherence to best practices in compound handling, solution preparation, and documentation is critical for reproducibility. For full product specifications, refer to the Omeprazole information page.